Skip to main navigation Skip to search Skip to main content

Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea

  • Eui Soon Kim
  • , Sun Kyeong Park
  • , Jong Chan Youn
  • , Hye Sun Lee
  • , Hae Young Lee
  • , Hyun Jai Cho
  • , Jin Oh Choi
  • , Eun Seok Jeon
  • , Sang Eun Lee
  • , Min Seok Kim
  • , Jae Joong Kim
  • , Kyung Kuk Hwang
  • , Myeong Chan Cho
  • , Shung Chul Chae
  • , Seok Min Kang
  • , Jin Joo Park
  • , Dong Ju Choi
  • , Byung Su Yoo
  • , Jae Yeong Cho
  • , Kye Hun Kim
  • Byung Hee Oh, Barry Greenberg, Sang Hong Baek
  • Korea Advanced Institute of Science and Technology
  • The Catholic University of Korea
  • Yonsei University
  • Seoul National University
  • Sungkyunkwan University
  • University of Ulsan
  • Chungbuk National University
  • Kyungpook National University
  • Yonsei University Wonju College of Medicine
  • Chonnam National University
  • Incheon Sejong Hospital
  • University of California at San Diego

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science